HOME >> MEDICINE >> NEWS
Drug-eluting stents adopted quickly, with early disparities

DURHAM, N.C. -- In the first comprehensive survey of its kind, Duke Clinical Research Institute researchers have documented that while the adoption of new drug-eluting stents has been rapid, their use has not been universally uniform among patients receiving them.

Furthermore, the researchers said, about one-third of the new stents were placed in patients with clinical characteristics for which such stent use has not yet been approved by the Food and Drug Administration (FDA). However, the researchers said that their finding of a high rate of "off-label" usage should be seen more as an impetus for further clinical trials rather than an immediate safety issue, since cardiologists have been placing traditional stents for more than 10 years and are comfortable with the procedure.

Stents are tiny mesh tubes that are inserted into the site of a blockage in a coronary artery that has been opened during balloon angioplasty. However, a principal complication of the procedure has been the high rate of treated arteries becoming blocked again, a process known as restenosis.

In an attempt to improve stents to keep treated arteries open, stent manufacturers coated them with a chemotherapeutic agent that limits the formation of scar tissue inside the artery. So far, clinical trials have shown that these new stents can reduce the restenosis rate to single digits from the 20 to 30 percent rate of the older stents. The first drug-eluting stent received FDA approval in April, 2003.

"Drug-eluting stents are truly breakthrough products in treating coronary artery disease, and in our analysis of the early trends of the their use, we found disparities in terms of age, race and socio-economic factors," said Duke cardiologist Sunil Rao, M.D., who presented the results of the Duke analysis Nov. 10, 2004, at the American Heart Association's annual scientific sessions in New Orleans.

"We also found that the rate of increased usage for off-label use was
'"/>

Contact: Richard Merritt
Merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
10-Nov-2004


Page: 1 2 3

Related medicine news :

1. Study finds drug eluting stents as effective as vascular brachytherapy in preventing restenosis
2. Study says rare allergic reactions to drug-eluting stents may raise risk for heart attack
3. Coronary stents do not improve long-term survival
4. Early reports of thrombosis after insertion of drug-eluting stents
5. Drug-coated stents effective in real world patients
6. Study highlights efficacy of sirolimus stents to prevent restenosis for PTS with CAD
7. Stanford computer model shows bypass surgery more cost-effective than stents
8. Research explores why some internationally adopted children excel while others struggle
9. Mandel School researchers receive $700,000 for study to promote well-being of adopted children
10. Sandia-developed foam likely would stop SARS virus quickly, Sandia/Kansas State team shows
11. New marker for early diagnosis of kidney failure identified

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drug eluting stents adopted quickly with early disparities

(Date:5/4/2015)... SACRAMENTO, Calif. (PRWEB) May 04, 2015 ... Permanente Medical Group today launched a new initiative ... building the next generation of physicians committed to ... Estudiantes Para Ser Medicos, or Preparing Students to ... multi-faceted initiative that will provide scholarships, mentorship and ...
(Date:5/4/2015)... Atlanta, Georgia (PRWEB) May 04, 2015 Each ... the country to raise funds and awareness for breast cancer. ... Plastic Surgery will be featured as the entertainment sponsor for ... the Cure” on May 9 at the Lenox Square Mall. ... year’s Atlanta race, and to raise $1.2 million. Perimeter Plastic ...
(Date:5/4/2015)... R.I. (PRWEB) May 04, 2015 Johnson & ... $40 million engineering and science academic center on Wednesday, April ... the ground for land made available by the re-alignment of ... the corner of Friendship and Chestnut streets in Providence, is ... built on a parcel of land the university purchased in ...
(Date:5/4/2015)... 04, 2015 The Lymphoma Research Foundation ... to funding innovative lymphoma research and serving the lymphoma ... initiatives and patient services – is set to host ... Farms in West Orange, NJ on June 1, 2015. ... innovative research programs through LRF. , This year, the ...
(Date:5/4/2015)... 04, 2015 Baptist Medical Center ... Association’s Get With The Guidelines®-Stroke Gold Plus Quality ... Roll. The award recognizes the hospital’s commitment and ... most appropriate treatment according to nationally recognized, research-based ... To receive the Gold Plus Quality Achievement Award, ...
Breaking Medicine News(10 mins):Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4
(Date:5/4/2015)... , May 4, 2015  By looking at ... to distinguish between two very different conditions that ... Theodore Henderson , MD, PhD., a ... cases, this study can help the ... therefore treatment options, for Post-Traumatic Stress Disorder (PTSD) ...
(Date:5/4/2015)... 2015  CytRx Corporation (Nasdaq: CYTR ), ... oncology, today announced an interim analysis from its ... aldoxorubicin with either gemcitabine or ifosfamide. Both studies ... escalating doses of aldoxorubicin. The combinations appear to ... dose level of aldoxorubicin (170 mg/m2), impressive tumor ...
(Date:5/4/2015)... CONCORD, N.H. , May 4, 2015 /PRNewswire/ ... creating analytic and technology solutions to improve healthcare ... Bedford Nursing & Rehabilitation Center (BNRC) use ... monitoring platform to improve the quality and lower ... analytics platform integrates clinical, outcomes, claims and utilization ...
Breaking Medicine Technology:New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3
Cached News: